Regeneron delivered the inflection quarter that the Sanofi profit-share math had been pointing toward, and then some. Non-GAAP EPS of $20.07 beat the $16.11 consensus by 19.5% and cleared the $16.79 Earnings Whisper number comfortably. Revenue of $5.116 billion topped the $4.55 billion estimate by 12.4%. Growth accelerated sharply. Earnings rose 72.9% year over year, and revenue grew 36.3%, after revenue gains of 19% and 17% in the first two quarters and just 3% in the fourth quarter of 2025. Income from operations roughly doubled to $2.05 billion. The central tension is that the acceleration came overwhelmingly from Dupixent economics flowing through the Sanofi collaboration, while the products Regeneron sells itself grew a more modest 14%, and its ophthalmology base is still shrinking.

The quality of the beat deserves scrutiny. Sanofi collaboration revenue jumped 68% to $2.72 billion. Regeneron's share of antibody profits rose to $2.575 billion from $1.456 billion. Part of that is genuine demand: Dupixent sales rose 35% to $6.5 billion, with U.S. sales above $5 billion. Part is structural. The Sanofi Development Balance was fully repaid at the end of the second quarter, so the third quarter was the first in which it no longer reduced collaboration revenue. That step-up is real and recurring, but it flatters the year-over-year comparison.

The call also flagged several items unlikely to repeat:

• an approximately $60 million Ilaris royalty catch-up;
• end-of-quarter retinal shipment timing;
• favorable gross-to-net adjustments.

On a GAAP basis, EPS rose a more muted 35% to $18.45. The main drag was much lower gains on securities, which fell to $60 million from $578 million a year earlier. Nine-month free cash flow of $2.9 billion trailed the prior year's $3.16 billion despite the earnings surge.

Beneath the Dupixent tailwind, the operating picture is mixed:

• **Libtayo:** Growth accelerated to 51%, reaching $550 million, up from 29% growth in the second quarter. U.S. sales rose 81%.
• **EYLEA HD:** U.S. sales climbed 62% to $699 million. The product now represents roughly two-thirds of the U.S. retinal franchise, and management guided full-year growth above 50%.
• **EYLEA 2mg:** U.S. sales collapsed 41% to $400 million as biosimilar competition expands. Combined U.S. EYLEA sales slipped 1%.
• **Bayer:** Collaboration revenue fell 23%.
• **Forward EYLEA guidance:** Management guided EYLEA HD fourth-quarter sequential demand growth to roughly 10%. That is softer than the low-to-mid-teens it framed for the second half on the prior call, and it comes with ongoing pricing pressure. EYLEA 2mg demand is expected to decline another low-to-mid-teens percentage in the fourth quarter.

The ophthalmology story is a transition, not yet a growth engine.

Full-year guidance moved favorably on the margin line. Non-GAAP gross margin on net product sales was lifted to about 86% from 84%–85%, and non-GAAP SG&A was cut by $100 million. R&D guidance rose by a similar amount. That trade-off previews the larger debate for 2027. Management expects R&D to rise mid-teens percent and the tax rate to climb 100–200 basis points, which will pressure operating leverage just as the Sanofi comparison normalizes.

The pipeline offers the counterweight, and the call preserved a credible growth story:

• The expanded Sanofi alliance adds four long-acting next-generation immunology antibodies on 50/50 terms. It carries a $1.0 billion upfront payment to be booked in the fourth quarter and up to $7.0 billion in milestones.
• A CIDEB-targeting RNAi therapy cut liver fat about 70% from a single dose, and a MASH/MASLD Phase 3 is slated to start this quarter.
• Ubamatamab posted roughly a 70% response rate in low-grade serous ovarian cancer.
• POTS data are due in November, and Pasatru was approved for FOP.
• Near-term regulatory decisions include cemdisiran in November, odronextamab in February 2027, and Libtayo every-six-week dosing in March 2027.
• On the negative side, the geographic atrophy interim readout slipped to early 2027.

Investor sentiment remained negative but improved modestly, rising to -0.21 from -0.29 at the prior report. Expectations were still skeptical even as the stock rallied. Shares entered the report at $818.77, up 16.7% from the open after the July release. They sat 11.1% above the 200-day moving average and about 4.7% below the $859.34 52-week high set on September 3. The Earnings Whispers trend signals are uniformly positive. The market had already priced in a good deal of the Sanofi step-up, so the debate shifts to how much of this quarter is repeatable.

The bottom line is that Regeneron's beat was large and its acceleration was real, but much of it reflects a one-time reset in Sanofi accounting, layered on Dupixent strength and a handful of non-recurring items. Libtayo and EYLEA HD are performing, the balance sheet is strong with $16.2 billion in net cash, and the pipeline gained momentum. However, the softer EYLEA HD guide, the shrinking legacy retinal business, and rising 2027 R&D and tax burdens give bears legitimate ammunition. The next leg depends less on Dupixent and more on whether the retinal transition and the late-stage pipeline can carry growth once the comparison advantage fades.